M&A

The major CRO acquisition deepens Worldwide's oncology and FSP capabilities, signaling a strategic move in the consolidating clinical research market.

Align Partners launches a major governance overhaul campaign at Dentium, aiming to fix the 'Korea discount' and unlock value at the undervalued market leader.

Partners Capital closes its largest co-investment fund at over $1B, signaling intense investor appetite for direct private equity deals in the middle market.

With major acquisitions complete, Huntington's leadership will face investors to outline their vision for growth amid a complex economic landscape.

Amid rising drug price scrutiny, Red Nucleus acquires an AI-powered consultancy to revolutionize how biopharma proves the value of new medicines.

With surging revenues and a new body contouring system, Apyx Medical heads to the BTIG conference to prove its growth story is here to stay.

In a planned leadership evolution, Daryl Seaton becomes CEO as founder Bill Sowell targets M&A, positioning the RIA for its next chapter of expansion.

WeShop adds Booking.com and Expedia, letting you earn company stock on vacation bookings. But financial data reveals a turbulent journey ahead for shoppers.

With an oversubscribed offering, Bravo Mining is set to accelerate its Luanga project, capitalizing on strong investor confidence and a bullish metals market.

Sichenzia Ross Ference Carmel LLP leveraged its deep expertise in complex securities to advise on over $14 billion in deals, outperforming in a hot market.

A new PwC survey shows CEO optimism plummeting as most firms fail to monetize AI, while a select few reap huge rewards, widening a dangerous gap.

Toro Corp. paid a massive special dividend, exciting investors. We dig into the cash-vs-stock option, market reaction, and what it means for the firm's future.

An independent ruling ends a financial dispute over a 2022 divestment, freeing Agfa to inject fresh capital into its high-growth transformation strategy.

With gold and silver prices soaring, Summit Royalties makes a strategic move onto the US OTCQB market to fuel its ambitious acquisition-led growth plan.

Ocugen heads to a top investor conference with a bold plan for its gene-agnostic therapy, aiming to treat blindness and secure its future in a crowded market.

Bio-Rad's leadership will meet investors at the J.P. Morgan conference, facing questions on strategy and growth in a competitive, tech-driven market.

CDT Equity partners with a top advisory firm to license its drug-enhancing tech, tackling the patent cliff while managing a novel Bitcoin treasury strategy.

Hyatt finalizes a $2B asset sale to Tortuga Resorts, advancing its asset-light strategy while navigating hurricane recovery in the Caribbean.

The regional bank sold $360M in low-yield securities, accepting a major one-time loss to reinvest for higher returns and a stronger 2026 outlook.

With industry veteran Kevin Muskat at the helm, Leon Capital Group's new advisory practice promises M&A guidance free from audit firm conflicts.